Innovent Biologics, Inc. (IVBXF)
Innovent Biologics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Suzhou, JS, CN. The stock last traded at $12.37, down 0.21% on the session, giving a market capitalisation of $21.54B. On trailing twelve-month figures it carries a trailing P/E of 164.81, a net margin of 6.2%. Its beta of 0.23 implies it has historically moved less than the broad market.
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. It specializes in the discovery, advancement, and production of antibody-based drug candidates, with a strategic focus on therapeutic areas including cancer treatment (oncology), eye conditions (ophthalmology), immune system disorders (immunology), and metabolic ailments. Innovent's flagship therapeutic offering is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in managing various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Additionally, its portfolio includes several other approved treatments: Byvasda, for diverse malignant tumors; Halpryza, addressing non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with advanced or metastatic cholangiocarcinoma; Olverembatinib, developed for adult patients requiring tyrosine kinase inhibitor treatment; and Cyramza, which targets four distinct cancer types. Beyond its commercialized products, Innovent maintains a robust pipeline of investigational therapies. These include IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody designed to combat hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody being explored for liver cancer and renal cell carcinoma. The company is also advancing IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy targeting relapsed or refractory multiple myeloma in adults; IBI-376, for recurrent or refractory follicular lymphoma; and IBI-112, designated for psoriasis. Moreover, Innovent provides pharmaceutical product distribution services, alongside offering expert consultation and engaging in research and development activities. Its operational strategy is further bolstered by strategic alliances with partners such as NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
Innovent Biologics, Inc. is most often compared with the following Healthcare names: